PLUR
Pluri, Inc.
NASDAQ · Healthcare · Biotechnology · IL
$0.85
−8.58%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.90
From 52W high−80.90%
Volume7992.00
Market cap$10.72M
P/E (TTM)—
P/S (TTM)10.6x
Div yield—
Key dataOct 19, 2026
Open
$0.90
From 52W high
−80.90%
Volume
7992.00
Market cap
$10.72M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.8x
P/E (TTM)
—
RSI (14)
33.0
MomentumView details →
1D Return
−8.58%
YTD Return
−68.90%
SummaryUpdated Jun 1, 2026
Pluri Inc. (NASDAQ:PLUR) is an Israeli biotechnology company founded in 2001 and headquartered in Haifa, Israel. Originally incorporated as Pluristem Therapeutics Inc., the company rebranded to Pluri Inc. in July 2022. The company went public in 2003 and has been developing innovative cell therapy treatments for over two decades. Pluri specializes in creating therapeutic products derived from placental cells, focusing on treating inflammatory conditions, muscle injuries, and blood-related disorders through its proprietary placental expanded (PLX) cell therapy platform.
Similar companies
Latest newsMore news →
Pluri Inc. priced a registered direct offering and concurrent private placement of 2,228,940 common shares at $1.50 per share to a single healthcare-focused institutional investor, expecting gross proceeds of approximately $3.3 million.53d agoPluri Inc.'s subsidiary Cellav completed cosmetic regulatory registration in the UK for its regenerative aesthetics product Regenativo+.83d ago